clinical trial · NCT04247906
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)Narsoplimab
brief summary
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.
started
—
primary completion
—
completion
—
last updated
Mar 5, 2026
official title
Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol